JPRN-UMIN000005573已完成未知
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia in chronic kidney disease. - The effects and safety of febuxostat in chronic kidney disease.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.The patients who are contraindicated to use febuxostat or allopurinol. 1)Patients who have liver injury(The ALT more than 200 IU/L) 2) Woman who is pregnat. 3) Patients who have allergy to febuxostat or allopurinol. 2. Patients who are judged as inadequate to participate the study by the their doctors.
研究者
相似试验
已完成
3 期
A clinical trial to study the effect of two drugs, febuxostat and allopurinol in chronic management of hyperuricemia in patients with gout.CTRI/2009/091/000611Sun Pharmaceutical Industries Limited200
招募中
不适用
effects of Uric-acid-lowering agent, FebuxOstat on subclinical inflammation in patients with hyperuricemia (UFO study)hyperuricemiaJPRN-UMIN000009262FO study Investigators100
已完成
不适用
Effect of urate LowEring Agent Febuxostat in Chronic Heart Failure patients with hyperuricemiaChronic heart failure patients with hyperuricemiaJPRN-UMIN000013330EAF-CHF steering committee200
已完成
2 期
Evaluation of safety and protective efficacy of fulminant hepatitis to abatacept treatment of patients with HBV-related severe hepatitis.-Pilot StudyHBV-related acute severe hepatitisJPRN-UMIN000025725Hiroshima university hospital10
已完成
不适用
The effectiveness and safety of fucoidan for atopic dermatitisSkin and Connective Tissue DiseasesAtopic dermatitisISRCTN90251749inkou Chang Gung Memorial Hospital91